This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 4, 2012 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it will present scientific data from one oral and 16 poster presentations at the American Psychiatric Association (APA) 165th Annual Meeting to be held
May 5-9. The data being presented represent Shire's ongoing commitment to the clinical research of Vyvanse
® (lisdexamfetamine dimesylate) Capsules, (CII) and INTUNIV
® (guanfacine) Extended-Release Tablets, its approved treatments for ADHD. In addition to ADHD research, data being presented will focus on investigational research in other psychiatric and neurobehavioral disorders, such as major depressive disorder and negative symptoms of schizophrenia. Shire also will present health economic outcomes research, as part of the company's efforts to develop cost-effective treatments for ADHD.
The new research poster entitled, "The Hidden Costs of Attention Deficit/Hyperactivity Disorder (ADHD): A Focus on School and Work in
the United States," was selected by the American Psychiatric Association to be highlighted at a special press briefing to be held during the meeting on
Sunday, May 6, at
11:30 am in the
Pennsylvania Convention Center room 104B.
"As a leader in the field of ADHD, Shire is committed to continuously expanding research in this and other psychiatric disorders, as evidenced by the breadth of data being presented at this important meeting," said
Jeffrey Jonas, M.D., Senior Vice President of Research and Development for Shire's Specialty Pharmaceuticals and Regenerative Medicine Businesses. "With these data, we seek to further advance the body of scientific and health economics knowledge across a range of serious conditions that present significant challenges for patients including ADHD, major depressive disorder, and negative symptoms of schizophrenia."
Vyvanse is a prescription medicine currently approved in
the United States and
Canada, as well as in
Brazil under the name Venvanse, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Vyvanse should be used to treat only ADHD.
Vyvanse is a Schedule II controlled substance. Stimulants, such as amphetamines and methylphenidates, are subject to misuse, abuse, addiction, and criminal diversion. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events.